Investors & Media Press Releases

Axovant Sciences Ltd. Announces Pricing of Initial Public Offering


HAMILTON, Bermuda, June 10, 2015 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering of 21,000,000 common shares at a price of $15.00 per share. The common shares of Axovant Sciences Ltd. have been approved for listing on the New York Stock Exchange and are expected to begin trading under the ticker symbol "AXON" on June 11, 2015. All of the common shares are being offered by Axovant Sciences Ltd. In addition, Axovant Sciences Ltd. has granted the underwriters a 30-day option to purchase up to 3,150,000 additional common shares.

Jefferies LLC, Evercore Group L.L.C. and RBC Capital Markets LLC are acting as joint book-running managers for the offering. JMP Securities LLC is acting as lead manager, and Robert W. Baird & Co. Incorporated is acting as co-manager for the offering.

The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail:; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, telephone: (212) 653-9054 or email:; or RBC Capital Markets, LLC, Attention: Prospectus Department, Brookfield Place, 200 Vesey Street 8th Floor, New York, NY 10281, telephone: (877) 822-4089, email:

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on June 10, 2015. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Axovant 
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, behavioral and functional components of dementia, a condition characterized by significant decline in mental capacity and impaired daily function.

Logo -

SOURCE Axovant Sciences Ltd.

Jonathan Neely
Head, Investor Relations and Corporate Communications
Axovant Sciences, Inc.
(212) 634-9744